EP3790628A4 - Zusammensetzungen und verfahren zur verminderung des fortschreitens von nephrolithiasis - Google Patents

Zusammensetzungen und verfahren zur verminderung des fortschreitens von nephrolithiasis Download PDF

Info

Publication number
EP3790628A4
EP3790628A4 EP19798912.2A EP19798912A EP3790628A4 EP 3790628 A4 EP3790628 A4 EP 3790628A4 EP 19798912 A EP19798912 A EP 19798912A EP 3790628 A4 EP3790628 A4 EP 3790628A4
Authority
EP
European Patent Office
Prior art keywords
nephrolithiasis
compositions
methods
reducing progression
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19798912.2A
Other languages
English (en)
French (fr)
Other versions
EP3790628A1 (de
Inventor
Demetrios Braddock
Clemens BERGWITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP3790628A1 publication Critical patent/EP3790628A1/de
Publication of EP3790628A4 publication Critical patent/EP3790628A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP19798912.2A 2018-05-08 2019-05-07 Zusammensetzungen und verfahren zur verminderung des fortschreitens von nephrolithiasis Pending EP3790628A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862668293P 2018-05-08 2018-05-08
PCT/US2019/031049 WO2019217373A1 (en) 2018-05-08 2019-05-07 Compositions and methods for reducing progression of nephrolithiasis

Publications (2)

Publication Number Publication Date
EP3790628A1 EP3790628A1 (de) 2021-03-17
EP3790628A4 true EP3790628A4 (de) 2022-03-09

Family

ID=68466827

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19798912.2A Pending EP3790628A4 (de) 2018-05-08 2019-05-07 Zusammensetzungen und verfahren zur verminderung des fortschreitens von nephrolithiasis

Country Status (6)

Country Link
US (1) US20210363506A1 (de)
EP (1) EP3790628A4 (de)
JP (1) JP2021523139A (de)
AU (1) AU2019267545A1 (de)
CA (1) CA3099266A1 (de)
WO (1) WO2019217373A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116406281A (zh) * 2020-05-27 2023-07-07 依诺兹梅制药公司 用于治疗外周动脉疾病的组合物和方法
MX2022015772A (es) * 2020-06-09 2023-05-19 Inozyme Pharma Inc Proteínas enpp1 o enpp3 solubles y sus usos.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039994A2 (en) * 2000-11-20 2002-05-23 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
WO2006135925A2 (en) * 2005-06-10 2006-12-21 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
WO2008105911A2 (en) * 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
WO2016187408A1 (en) * 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2014152940A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
AU2015364411A1 (en) * 2014-12-19 2017-06-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
EP3452101A2 (de) * 2016-05-04 2019-03-13 CureVac AG Rna-codierung eines therapeutischen proteins
EP3493829B1 (de) * 2016-08-05 2024-04-17 Yale University Zusammensetzungen und verfahren zur schlaganfallvorbeugung in pädiatrischen patienten mit sichelzellanämie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039994A2 (en) * 2000-11-20 2002-05-23 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
WO2006135925A2 (en) * 2005-06-10 2006-12-21 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
WO2008105911A2 (en) * 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
WO2016187408A1 (en) * 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019217373A1 *

Also Published As

Publication number Publication date
EP3790628A1 (de) 2021-03-17
JP2021523139A (ja) 2021-09-02
AU2019267545A1 (en) 2020-11-26
CA3099266A1 (en) 2019-11-14
US20210363506A1 (en) 2021-11-25
WO2019217373A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
EP3823673A4 (de) Anti-cd112r-zusammensetzungen und verfahren
EP3589291A4 (de) Zusammensetzungen und verfahren zur hemmung von zelllinienspezifischen proteinen
EP4054621A4 (de) Zusammensetzungen und verfahren zur rna-codierten dna-ersetzung von allelen
EP3826638A4 (de) Elagolix-natrium-zusammensetzungen und verfahren
EP3735325A4 (de) Oberflächenbehandlungszusammensetzungen und -verfahren
EP3829307A4 (de) Wismuth-thiolzusammensetzungen und verwendungsverfahren
EP3863630A4 (de) Zusammensetzungen und verfahren zur behandlung von presbyopie
EP3807319A4 (de) Zusammensetzungen und verfahren zur induzierung von phagozytose
EP3833340A4 (de) Zusammensetzungen und verfahren zur behandlung von presbyopie
EP3844500A4 (de) Rp182-zusammensetzungen und verfahren
EP3768301A4 (de) Zusammensetzungen und verfahren zur fas-hemmung
EP3843729A4 (de) Neuartige zusammensetzungen und verfahren
EP3893901A4 (de) Zusammensetzungen und verfahren für immuntherapien
EP3840769A4 (de) Cyclosporinzusammensetzungen und verfahren zur verwendung
EP3836938A4 (de) Feste formen von substituiertem benzoxazol und zusammensetzungen davon
EP3830196A4 (de) Oberflächenbehandlungszusammensetzungen und -verfahren
EP3790628A4 (de) Zusammensetzungen und verfahren zur verminderung des fortschreitens von nephrolithiasis
EP3740500A4 (de) Zusammensetzungen und verfahren zur erhöhung der expression von scn2a
EP3463322A4 (de) Verfahren und zusammensetzungen zur behandlung von hyperkalziurie und nephrolithiasis
EP3965776A4 (de) Oligosaccharidzusammensetzungen und verfahren zur verwendung
EP3880191A4 (de) Zusammensetzungen und verfahren zur verbesserten immuntherapie
EP3856184A4 (de) Zusammensetzungen und verfahren zur hemmung von acss2
EP3902976A4 (de) Verfahren und zusammensetzungen zur behandlung von kalk
EP3917320A4 (de) Bakterizide verfahren und zusammensetzungen
EP3866810A4 (de) Verfahren und zusammensetzungen zur behandlung von oraler mukositis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048156

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220209

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 13/04 20060101ALI20220203BHEP

Ipc: A61K 38/46 20060101ALI20220203BHEP

Ipc: C12N 9/16 20060101ALI20220203BHEP

Ipc: A61P 13/12 20060101AFI20220203BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

17Q First examination report despatched

Effective date: 20230526